KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101).

Takaaki Tanaka, Go Makimoto, Naoki Nakamura, Yuka Kato, Isao Oze, Toshihide Yokoyama, Shoichi Kuyama, Satoru Senoo, Koji Inoue, Hirohisa Ichikawa, Yoshinobu Maeda, Yosuke Togashi, Katsuyuki Hotta

Oncologist 31(10) oyag352

PMID42750137
PMCIDPMC13612169
DOI10.1093/oncolo/oyag352
发表日期2026-09-17
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy. MATERIALS AND METHODS: In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for ≥4 courses of carboplatin plus PTX (≥150 mg/m²) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade ≥2 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (α = 0.10); a supportive stratified analysis accounted for the minimization factors. RESULTS: Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade ≥2 CIPN occurred in 28.1% (9/32) of the GJG arm vs 51.5% (17/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P = .101). Grade 3-5 adverse-event incidence was similar between arms. CONCLUSION: GJG was associated with fewer grade ≥2 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial. CLINICAL TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials (jRCTs061210047).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。